News about Market

Samsung Bioepis Relaunches Byooviz in US Through Commercial Partnership with Harrow

Samsung Bioepis has relaunched its ophthalmology biosimilar Byooviz in the US through its partnership with Harrow, expanding access to a lower-cost treatment option for patients with retinal diseases, including wet age-related macular degeneration.

Market | 03/07/2026 | By News Bureau

Mankind Pharma Partners with Denovo Sciences to Accelerate AI-Driven Drug Discovery

The collaboration between Mankind Pharma and Denovo Sciences launches AI-powered drug discovery to accelerate research timelines and improve lead candidate quality.

Market | 02/07/2026 | By News Bureau |  137

Innovent and Lilly Partner to Commercialise Verzenios in China

Innovent Biologics and Eli Lilly have signed a commercialisation agreement for Verzenios (abemaciclib) in mainland China, expanding access to the CDK4/6 inhibitor for cancer patients.

Market | 01/07/2026 | By News Bureau |  110

Jagsonpal Pharmaceuticals to Acquire 85 Percent Stake in Aequitas Healthcare for INR 20.8 Crore

Aeguitas Healthcare’s acquisition marks Jagsonpal's entry into the hospital pharmaceutical segment, strengthening its omnichannel healthcare strategy and expanding its institutional market presence.

Market | 01/07/2026 | By News Bureau |  150

Cadila Pharmaceuticals, Wellesta Forge Joint Venture to Expand Healthcare Footprint Across Southeast Asia

Cadila Pharmaceuticals and Singapore-based Wellesta Holdings have signed an MoU to establish a joint venture focused on expanding access to high-quality healthcare solutions across Southeast Asia and other emerging markets.

Market | 01/07/2026 | By News Bureau |  138

Morepen Begins Commercial Supplies under INR 825 Crore CDMO Contract

Morepen has started commercial supplies under its INR 825 crore CDMO mandate, completing the first INR 50 crore dispatch in Q1 FY2026-27 and strengthening its contract manufacturing business.

Market | 01/07/2026 | By News Bureau |  134

Aurobindo Pharma USA Completes Acquisition of Lannett Company

Aurobindo Pharma USA has completed the acquisition of Lannett Company after securing approval from the US Federal Trade Commission. Effective June 29, 2026, Lannett will operate as Lannett Company LLC, with the combined entity aiming to strengthen the supply of essential medicines and enhance value for patients and customers.

Market | 30/06/2026 | By News Bureau |  113

Universe Pharmaceuticals to Acquire Patent Holding Firm in USD 10.75 Million Share Deal

Universe Pharmaceutical’s acquisition will strengthen Best Praise International's intellectual property portfolio with five China-based pharmaceutical patents, supporting its long-term strategy to expand research, product development and commercial opportunities in elderly healthcare and age-related diseases.

Market | 30/06/2026 | By News Bureau |  229

Strides Pharma Divests Majority Stake in Pivot Path to Ascent Capital-Led Consortium for INR 100 Crore

Strides Pharma Science has sold a majority stake in its subsidiary, Pivot Path, to an Ascent Capital-led investor consortium for INR 100 crore, alongside a fresh INR 50 crore capital infusion that will support the company's expansion as an independent life sciences and digital transformation services provider.

Market | 29/06/2026 | By News Bureau |  125

BDR Pharma Launches Xatronem-AV to Combat Multidrug-Resistant Gram-Negative Infections

BDR Pharma introduces Xatronem-AV, a next-generation antibacterial therapy for serious multidrug-resistant Gram-negative infections.

Market | 26/06/2026 | By News Bureau |  290